|
Nov 5
|
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
|
|
Nov 4
|
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
|
|
Oct 30
|
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
|
|
Oct 23
|
Cellectis Presents New Gene-Editing Breakthroughs
|
|
Oct 22
|
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
|
|
Jan 16
|
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
|